ERBB2 and breast cancer: Supplementary Figure S4 shows the classification of subjects based on tumor growth characteristics by key prognostic factors. Similar to the observations in DB-03 study, T‐DXd demonstrated a consistent trend in reducing tumor growth(g) across the prognostic factors in DB-04 in the HER2‐low pretreated breast cancer population.